High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors

被引:14
|
作者
Ikezono, Yu [1 ,2 ]
Koga, Hironori [1 ,2 ]
Abe, Mitsuhiko [1 ,2 ]
Akiba, Jun [3 ]
Kawahara, Akihiko [2 ,4 ]
Yoshida, Takafumi [1 ,2 ]
Nakamura, Toru [1 ,2 ]
Iwamoto, Hideki [1 ,2 ]
Yano, Hirohisa [3 ]
Kage, Masayoshi [2 ,4 ]
Sata, Michio [1 ]
Tsuruta, Osamu [1 ]
Torimura, Takuji [1 ,2 ]
机构
[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 8300011, Japan
[2] Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 8300011, Japan
[3] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 8300011, Japan
[4] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka, Japan
关键词
carcinoids; neuroendocrine tumor; cancer stem cell; NANOG; DOUBLECORTIN-LIKE; NEUROBLASTOMA-CELLS; PANCREATIC-CANCER; TUFT CELLS; MECHANISM; INTESTINE; MIGRATION; GROWTH;
D O I
10.3892/ol.2015.3513
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Doublecortin-like kinase 1 (DCLK1), a microtubule-associated protein, is known to regulate neuronal differentiation, migration and neurogenesis. Recent evidence suggests that the protein is a putative marker for intestinal and pancreatic stem cells, including their cancer stem cell counterparts. The present study conducted immunohistochemical analyses for DCLK1 and the sternness marker, NANOG, in human intestinal neuroendocrine tumors (NETs), as their expression had not been previously investigated in these tumors. Eighteen patients with endoscopically resected rectal NETs were enrolled in the study. The mean age of the patients was 51 years old. The mean diameter of the resected tumors was 5.2 mm, and a histological diagnosis of NET grade G1 was formed for all tumors. Immunohistochemical analysis was performed not only for DCLK1, but also for the known NET markers, synaptophysin, chromogranin A and cluster of differentiation (CD)56. The intensity and distribution of staining were scored on a scale of 0-3 and 0-2, respectively. The sum of the scores was calculated for each specimen. Co-expression of DCLK1 and NANOG was also examined. The mean scores for DCLK1 and synaptophysin were significantly higher than those for chromogranin A (P<0.0001) and CD56 (P<0.01). There were no significant differences in the scores between DCLK1 and synaptophysin or between chromogranin A and CD56. Notably, NANOG was expressed in high quantities in all the tumor tissues studied, showing clear co-expression with DCLK1. In conclusion, DCLK1 may be a novel marker for rectal NET, potentially indicating the presence of the sternness gene product, NANOG.
引用
收藏
页码:2015 / 2020
页数:6
相关论文
共 50 条
  • [1] Human rectal carcinoid tumors highly express DCLK1, a putative cancer stem cell marker
    Ikezono, Yu
    Koga, Hironori
    Abe, Mitsuhiko
    Yoshida, Takafumi
    Nakamura, Toru
    Akiba, Jun
    Yano, Hirohisa
    Tsuruta, Osamu
    Torimura, Takuji
    Sata, Michio
    CANCER RESEARCH, 2014, 74 (19)
  • [2] DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma
    Lorenzo, Nevi
    Sabina, Di Matteo
    Guido, Carpino
    Grazia, Zizzari Ilaria
    Samira, Safarikia
    Valeria, Ambmsino
    Daniele, Costantini
    Diletta, Overi
    Antonella, Giancotti
    Marco, Monti
    Daniela, Bosco
    Valerio, De Peppo
    Andrea, Oddi
    Maria, De Rose Agostino
    Fabio, Melandro
    Consiglia, Bragazzi Maria
    Jessica, Faccioli
    Sara, Massironi
    Luca, Grazi Gian
    Benedetti, Panici Pierluigi
    Bartomeo, Berloco Paquale
    Felice, Giuliante
    Vincenzo, Cardinale
    Pietro, Invernizzi
    Giuseppina, Caretti
    Eugenio, Gaudio
    Domenico, Alvaro
    HEPATOLOGY, 2021, 73 (01) : 144 - 159
  • [3] Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1
    Ikezono, Yu
    Koga, Hironori
    Akiba, Jun
    Abe, Mitsuhiko
    Yoshida, Takafumi
    Wada, Fumitaka
    Nakamura, Toru
    Iwamoto, Hideki
    Masuda, Atsutaka
    Sakaue, Takahiko
    Yano, Hirohisa
    Tsuruta, Osamu
    Torimura, Takuji
    MOLECULAR CANCER RESEARCH, 2017, 15 (06) : 744 - 752
  • [4] DCLK1, a putative stem cell marker in human cholangiocarcinoma (vol 73, pg 144, 2021)
    Nevi, Lorenzo
    Di Matteo, Sabina
    Carpino, Guido
    Zizzari, Ilaria Grazia
    Safarikia, Samira
    Ambrosino, Valeria
    Costantini, Daniele
    Overi, Diletta
    Giancotti, Antonella
    Monti, Marco
    Bosco, Daniela
    De Peppo, Valerio
    Oddi, Andrea
    De Rose, Agostino Maria
    Melandro, Fabio
    Bragazzi, Maria Consiglia
    Faccioli, Jessica
    Massironi, Sara
    Grazi, Gian Luca
    Panici, Pierluigi Benedetti
    Berloco, Paquale Bartomeo
    Giuliante, Felice
    Cardinale, Vincenzo
    Invernizzi, Pietro
    Caretti, Giuseppina
    Gaudio, Eugenio
    Alvaro, Domenico
    HEPATOLOGY, 2022, 75 (03) : 773 - 773
  • [5] Divergent expression of DCLK1 in gastrointestinal neuroendocrine tumors and primary hepatic, gallbladder, and pancreatic neuroendocrine tumors
    Fan, Mengjiao
    Yan, Huan
    Gou, Miaomiao
    Qian, Niansong
    Dai, Guanghai
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (09): : 2249 - 2258
  • [6] The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
    Vedeld, Hege Marie
    Skotheim, Rolf I.
    Lothe, Ragnhild A.
    Lind, Guro E.
    EPIGENETICS, 2014, 9 (03) : 346 - 350
  • [7] A putative stem cell marker, doublecortin-like kinase (DCLK1), is involved in the development of hepatocellular carcinoma
    Ali, Naushad
    CANCER RESEARCH, 2013, 73 (08)
  • [8] Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer
    Kadletz, Lorenz
    Kenner, Lukas
    Wiebringhaus, Robert
    Jank, Bernhard
    Mayer, Christina
    Gurnhofer, Elisabeth
    Konrad, Stefan
    Heiduschka, Gregor
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [9] DCLK1 as a Promising Marker for Radioresistance in Colorectal Cancer
    Mohammadi, Chiman
    Najafi, Rezvan
    JOURNAL OF GASTROINTESTINAL CANCER, 2020, 51 (02) : 714 - 715
  • [10] DCLK1 as a Promising Marker for Radioresistance in Colorectal Cancer
    Chiman Mohammadi
    Rezvan Najafi
    Journal of Gastrointestinal Cancer, 2020, 51 : 714 - 715